The development of a mammalian brain is a complex and long-lasting process. Not surprisingly, preterm birth is the leading cause of death in newborns and children. Advances in perinatal care reduced mortality but morbidity still represents a major burden. New therapeutic approaches are thus desperately needed. Given that mesenchymal stem/stromal cells (MSCs) emerged as a promising candidate for cell therapy, we transplanted MSCs derived from the Wharton`s jelly (WJ-MSCs) to reduce the burden of immature brain injury in a murine animal model. WJ-MSCs transplantation resulted in protective activity characterized by reduced myelin loss and astroglial activation. WJ-MSCs improved locomotor behavior as well. To address the underlying mechanisms we tested the key regulators
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Abstract
The development of a mammalian brain is a complex and long-lasting process. Not surprisingly, preterm birth is the leading cause of death in newborns and children.
Advances in perinatal care reduced mortality but morbidity still represents a major burden. New therapeutic approaches are thus desperately needed. Given that mesenchymal stem/stromal cells (MSCs) emerged as a promising candidate for cell therapy, we transplanted MSCs derived from the Wharton`s jelly (WJ-MSCs) to reduce the burden of immature brain injury in a murine animal model. WJ-MSCs transplantation resulted in protective activity characterized by reduced myelin loss and astroglial activation. WJ-MSCs improved locomotor behavior as well. To address the underlying mechanisms we tested the key regulators of responses to DNA damaging agents such as cyclic AMP dependent protein kinase / calcium-dependent protein kinase (PKA/PKC), cyclin-dependent kinase (CDK), ataxia-telangiectasiamutated/ATM-and Rad3-related (ATM/ATR) substrates, Protein kinase B (Akt), and 14-3-3 binding protein partners. We characterized WJ-MSCs using a specific profiler PCR array. We provide evidence that WJ-MSCs target pivotal regulators of the cell fate such as CDK/14-3-3/Akt signaling. We identified leukemia inhibitory factor as potential candidate of WJ-MSCs` induced modifications as well. We hypothesize that WJ-MSCs may exert adaptive responses depending on the type of injury they are facing, making them prominent candidates for cell therapy in perinatal injuries. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 Preterm birth is a complex multifactorial syndrome and together with intrapartumrelated complications the leading cause of death in newborns and children [1, 2] . This is especially evident in very low gestational age infants (< 32 weeks gestation) where advances in perinatal care reduced mortality but morbidity still represents a major burden [3, 4] . The magnitude of this medical and socioeconomic burden is enormous.
Depending on the degree of prematurity, up to 20% of infants will develop spastic cerebral palsy (CP) and up to 50% demonstrate cognitive, behavioral, motor and sensory deficits, or higher incidence of psychiatric disorders [5] [6] .
In immature infants at risk, no individual protective agent has proven safe and effective so far [7-9]. Magnesium sulfate reduces the incidence of CP in the preterm population, but identification of pregnant mothers with anticipated preterm labor is difficult [10] . New therapeutic approaches are thus desperately needed. In recent years, mesenchymal stem/stromal cells (MSCs) emerged as a promising candidate for cell therapy targeted against perinatal brain injury [11]. MSCs isolated from the stroma of the umbilical cord (Wharton`s jelly; WJ-MSCs) [12, 13] are of special interest as they are easy available around the time of birth, an autologous source, and pose no ethical concerns [14, 15] . In addition, WJ-MSCs possess a low immunogenic capacity and a multipotent differentiation potential [13] . MSCs were shown to modulate innate and adaptive immune responses, to have anti-apoptotic effects, to decrease inflammation, and to enhance tissue repair, mostly through the release of paracrine factors [16, 17] .
The development of a mammalian brain is a complex and long-lasting process which follows specific time-and space-dependent sequences with interactions of various cell types. One of the common denominators is the dynamic equilibrium of cellular 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Protein kinase B (Akt), and 14-3-3 binding protein partners [20] [21] [22] [23] [24] [25] [26] . For example, activation of PKA/PKC signaling results in the protection of an immature brain [21] and CDK inhibition proved to be protective in stroke [19] . Activation of ATM/ATR signaling results in neuronal apoptosis [26] and Akt signaling is a well-defined prosurvival pathway [20] . Further, 14-3-3 proteins have been shown to be neuroprotective in a variety of neurological disorders [27, 28] . 14-3-3 proteins represent a homologous family which bind their substrates through an amphipatic binding cleft leading to a variety of effects including stress response, apoptosis, transcriptional regulation, cell cycle regulation [24] . Together, targeting these cell fate pathways represent a potential neuroprotective strategy in an immature brain.
In this report, we show the effect of WJ-MSCs in a clinically relevant murine model of immature brain injury. WJ-MSCs transplantation exerts protective effects at both histological and behavioral level. We provide evidence that WJ-MSCs target pivotal regulators of the cell fate as well. Our result support the notion of WJ-MSCs as an attractive cell graft in immature infants at risk. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Methods
All procedures have been approved by the local institutional review board (Ethics Committee and Veterinary Department of the Canton of Berne, Switzerland). We obtained a written informed consent from all umbilical cord donors.
Cell graft: Wharton's jelly-derived MSCs
Human WJ-MSCs were isolated and characterized as previously published [12, 29] . 
Animal Model: Perinatal Brain Injury
We induced immature brain injury as we had previously described [21, 30] . Briefly, neonatal Wistar rats were randomly divided into 3 groups (Sham, Injury, and Injury+WJ-MSCs; n=19). The Injury and Injury+WJ-MSCs groups received Lipopolysaccharides (LPS: 0.1mg/kg BW, i.p.) at postnatal day 3 (P3). On the following day, the left common carotid artery was double-ligated using a stereomicroscope and animals were subjected to mild hypoxia (8% O 2 / 92% N 2 ; 40 minutes). The Sham Group (n=6) consisted of uninjured animals (0.9% NaCl instead of LPS i.p., exposure of carotid artery without ligation, no hypoxia and no further treatment). The Injury+WJ-MSCs Group (n=7) received a single cell graft transplantation into the lateral ventricle. We transplanted 250'000 of WJ-MSCs into the left ventricle at postnatal day 11 as published previously [29] . Briefly, anesthetized animals were fixed on a block heated to 37°C in a small animal stereotaxic frame (David Kopf Instruments, Tujunga, CA). We injected a volume of 5µL over approx. 6 min into the lateral ventricle using a Lab Animal Studies Injector (Hamilton, Bonaduz, Switzerland) with a 32 gauge needle. The needle was left in place for 2 min after injection and then withdrawn slowly. The Injury Group (n=6) received no WJ-MSCs treatment but the needle was placed into the ventricle without vehicle injection.
Functional tests
To assess the functional outcome after brain injury, we performed a walking pattern analysis [31] . Briefly, rats with stained hind paws were placed on an inclining gangway and walked up the gangway and into a dark box. Paper strips with footprints were scanned and stride length (the distance between steps of the same side) and toe distance (distance between the 1st and 5th toe) were measured for the left and right hind paw. 
Tissue Harvesting and Immunohistochemistry
We performed brain harvesting on P39 (n=19; Fig. 1C ). Briefly, we deeply anesthetized animals with sodium thiopental (100mg/kg body weight i.p., Inresa, Freiburg, Germany) and sacrificed by cardiac perfusion with PBS followed by formaldehyde (4%; Merck, Darmstadt, Germany). Animals were decapitated and we removed brains surgically and fixed in formaldehyde solution (4%) for 2-4 hours at room temperature (RT) followed by 4°C for a total time of 24-48 hours. Fixed brains were embedded in paraffin and sectioned into 7µm slices.
For further details on tissue immunohistochemistry see Supplementary Information

Tissue Harvesting and Western Blots
To dissect WJ-MSCs protective mechanisms in the brain tissue (n=3 each group), we induced brain injury as described above with following changes (see Supplementary Information for details). Whole brain lysates for kinome profiling were isolated following a protocol developed by Cell Signaling Technology (Danvers, MA 
Induction of WJ-MSC into neural progenitor cells and gene Array
To further characterize WJ-MSCs, we differentiated them at cell culture passage 5
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Quantitative Assessment of the Brain
We performed quantitative assessments in the region of interest (ROI) defined as deep cerebral cortex (cortical layers V and VI in Figure 108 according to a neonatal rat brain atlas) [34] and in each hemisphere independently. Notably, ROI is the expected area of injury and hypoxia-ischemia was reported to cause distinctive neuropathological alterations in these regions of the parieto-occipital cortex and white matter tracts [21, 30, 35] . We acquired images using a BX51 microscope (Olympus, Tokyo, Japan) with a 40× objective and equipped with a digital camera. An independent observer acquired six consecutive ROI sections visual field by visual field without overlapping per hemisphere and animal for each specific immunostaining blinded to the experimental conditions. To asses myelin loss (MBP immunostaining) and astrogliosis (GFAP immunostaining), we measured the percentage of positive MBP and GFAP staining (area) in the ROI in each hemisphere as described previously [36, 37] . We determined the difference between contralateral (undamaged) and ipsilateral (damaged) hemispheres using Image J [32].
Data analysis
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Results
WJ-MSCs as a cell graft
We decided to use WJ-MSCs as a cell transplant as they are considered an attractive source for perinatal transplantation [11, 40] . The isolated WJ-MSCs were adherent to plastic and displayed a fibroblast-like phenotype (Fig. 1A) [33]. Further, after five passages, we detected characteristic MSCs cell surface markers ( Fig. 1B) [41]. To test our hypothesis that our cell graft protects the immature brain, we used a wellestablished murine model (Fig. 1C ) [21, 30] . We evaluated the migration of WJ-MSCs by staining for HLA-ABC-positive cells at P39. In line with previous studies, we detected only few positive cells ( Fig. 1D) [42] in the cortex cerebri, hippocampus and striatum [29] . We did not detect any signs of differentiation in line with previous studies [43, 44] .
WJ-MSCs protect against immature brain injury
To test the effectiveness of WJ-MSCs treatment in immature brain injury, we evaluated loco-motor behavior first ( Fig.2A ). In line with previous reports, we detected abnormal walking behavior after the brain insult, namely a significant change of step length and toe distance ( Fig.2A ; compare left to right hind paws' step length and toe distance of Injury vs. Sham groups) [31] . WJ-MSCs transplantation resulted in the alleviation of spastic paresis and restored motor symmetry ( Fig.2A ;
compare left to right hind paws' step length and toe distance of Injury vs. Injury+WJ- MSCs groups). To determine the underlying pathophysiology, we focused on the motor cortex with emphasis on the characteristic deep cortical layers as these regions are altered as a consequence of immature brain injury [35, 45] and associated with impaired loco-motor behavior [31] .
We evaluated the number of NeuN-positive cells (mature neurons) in deep cortical layers first, as injury and hypoxia-ischemia at this time point were reported to cause distinctive neuropathological alterations in these regions [21, 30, 35 ]. We did not detect neuronal loss ( Fig.2B ; compare ipsilateral injured to contralateral intact hemisphere Sham vs. Injury) [36, 46] . However, we need to consider that in contrast to our previous studies [21, 30] , we induced a "mild" injury (hypoxia reduced to 40 minutes). Additionally, the most common neuropathology in premature infants is not focal necrosis but diffuse non-cystic alterations [14, 18] . As these alterations evolve over time to glial scars characterized by microgliosis and astrogliosis, we tested them next.
Given that the hallmark of immature brain injury is the degeneration of immature oligodendrocytes and a resulting loss of mature oligodendrocyte markers like myelin basic protein (MBP), we tested for myelin loss [47] [48] [49] . We detected a significant myelin loss after injury ( 
WJ-MSCs modulate PKA/PKC, CDK, Akt signaling, and 14-3-3 binding in the immature brain
Our results indicate that transplantation of WJ-MSCs protects the immature brain against injury ( Fig. 2 compare Injury vs. Injury+WJ-MSCs groups). However, the underlying mechanisms remain unclear. To investigate these mechanisms, we chose a global screening approach to detect key regulators of responses to DNA damage and probed the brain tissues against well-characterized motif specific antibodies [21] .
These antibodies detect specific post-translational modifications in the context of specific binding motif or substrate. Thus, we assess not a single target but rather have a global overview.
We tested PKA/PKC first as they are important signaling molecules in a variety of cellular functions including cellular response to hypoxia-ischemia or oxidative stress [21, 53, 54] . In line with previous reports, injury to an immature brain resulted in the activation of PKA/PKC signaling (Fig.3A ) [21] . Surprisingly, WJ-MSCs did not further activate PKA/PKC but rather decreased it significantly (Fig.3A) .
In search for other potential mechanisms and given the emerging importance of CDK inhibitors in oncology and their potential use in stroke, we tested for CDK substrates [19] . In stroke, ischemic brain injury results in an activation of CDK signaling and CDK inhibition is protective [19] . Immature brain injury did not affect CDK signaling and we detected CDK activation after cell graft transplantation ( Fig.3B ). To further elucidate the graft response, we tested ATM/ATR signaling as ATM is upstream of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 15 CDK in cell cycle arrest [26, 55, 56] . We did not detect any significant changes ( Fig.3C ), which suggests that the observed cell graft-mediated CDK activation is ATM/ATR-independent. Next, we tested phosphorylated Akt substrates and 14-3-3
binding partners as they modulate the cell cycle progression, are crucial CDK partners, and reported neuroprotective targets [20, 24, 57, 58] . In line with CDK activation, WJ-MSCs treatment increased phosphorylation of Akt substrates and 14-3-3 binding partners ( Fig.3D and E) . Together, our results provide evidence that WJ-MSCs protect the immature brain and modulate cell fate signaling pathways (Fig. 3F) involved in brain protection.
WJ-MSCs express neurotrophic factors
Given the modifications after transplantation of WJ-MSCs ( Fig. 3 ) and WJ-MSCs`
protective effects (Fig. 2) , we aimed to further characterize the cell graft using a gene array [33] . We decided to compare WJ-MSCs to differentiated neurospheres derived from WJ-MSCs as WJ-MSCs have a "multi-differentiated" potential. It is the potential to express factors from other tissues before any differentiation. Thus, we aimed to detect changes unique to the relatively heterogeneous cell population of WJ-MSCs
[33]. In line with this potential, we detected increased expression of neurotrophic factors and receptors involved in brain development and response to injury such nerve growth factor receptor (NGFR) and GDNF family receptor alpha 3 (GFRA3) [59, 60] (all genes summarized in Table 1 ). We detected increased expression of Prostaglandin E receptor 2 (PTGER2) which in stroke protects against oxidative stress in a PKA dependent manner [61] . Interestingly, we detected increased expression of leukemia inhibitory factor (LIF) as well. LIF is an important factor contributing to a variety of cellular processes such as neuronal development, astroglial responses to injury, and oligodendrocyte survival [62] [63] [64] [65] . Importantly, LIF exerts its biological effects partially through Akt, CDK, and 14-3-3 signaling pathways 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 . 3) . We confirmed increased LIF expression in WJ-MSCs on protein level as well ( Fig. 3G ).
Together, we hypothesize that WJ-MSCs may exert adaptive responses depending on the type of injury they are facing, making them prominent candidates for cell therapy in perinatal injuries.
Discussion:
This report documents that WJ-MSCs transplantation exerts protective effects against immature brain injury. Using a clinically relevant model, we demonstrate that our cell graft (Fig. 1) is able to ameliorate myelination loss and astroglial activation while preserving proper functional behavior (Fig.2) . Most importantly, we are the first to report that WJ-MSCs target crucial signaling pathways involved in cell cycle regulation and apoptosis (Fig. 3F ), while expressing growth and differentiation factors (Tab. 1). Together, we provide evidence that WJ-MSCs are potential candidates for treatment of immature infants at risk.
MSCs and MSC-derived therapies emerged in the last decades as a potential paradigm-shift for complex multifactorial diseases such as immature brain injuries [68] . As the preterm infant faces multiple risk factors including inflammation/infection, ischemia/reperfusion, and deprivation of placental protective factors, an optimal therapeutic should target the injuries globally (several organs) and locally (response to signals of local injury) [11] . In our study, WJ-MSCs protect the immature brain and modulate different signaling pathways. This is particularly interesting as it fuels the constant debate whether MSCs or MSC-derived products such as conditioned media or exosomes are the optimal choice for treating perinatal injuries. We hypothesize that the WJ-MSCs' ability to locally respond to signals after injury is an advantage, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 18 Numerous studies postulate that MSCs protective effects after perinatal injury are based on paracrine effects and immunomodulation [11] . In contrast to upcoming novel immunomodulation therapies such as PreImplantation Factor, WJ-MSCs did not impact PKA/PKC signaling after injury [21] . Given the diverse modes of action, a combined therapeutic approach may provide superior protection due to synergistic effects. Another surprising finding is that WJ-MSCs activate CDK signaling in the brain while CDK inhibition protects neurons in stroke or traumatic brain injury [19, 73] .
However, when considering this opposite effects, the distinct pathophysiology of an immature brain and time point of the evaluation need to be accounted for. For example, in an immature brain, cell proliferation and differentiation, especially in the case of oligodendrocyte progenitors, depend on proper CDK activity [55, 74] . Further, in stroke CDK activation was detected up to 24 hours of reperfusion injury only [19] .
Given that CDK modulation was not detected after injury ( suggest an age-dependent role of CDKs. Together, we provide evidence that WJ-MSCs modulate crucial cell fate pathways in an immature brain injury setting. We hypothesize that targeting these pathways impacts the regeneration capacity of a developing brain. Additional studies will dissect which specific pathways such as AKT/CDK/14-3-3 binding and factors such as LIF may produce beneficial effects.
Furthermore, studies addressing the direct comparison of different cell transplants including adipose-derived stem cells and bone marrow mononuclear cells will determine whether the documented effects ( Fig. 3) are WJ-MSCs specific as well.
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WJ-MSCs modulate crucial cell fate pathways
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SUPPLEMENTARY METHODS
Perioperative Care of the Animals
Perioperative care was performed in accordance with Ethics Committee and Veterinary Department of the Canton of Berne, Switzerland guidelines.
Acclimatization of animals to the laboratory environment was allowed prior to surgery.
Aseptic rodent survival surgery guidelines were followed. We injected Buprenorphine (0.1 mg/kg body weight) subcutaneously (s.c.) 30 min prior incision. Carprofen was used for postoperative analgesia (5 mg/kg, s.c., starting 4-6 hours post-surgery, every 24 hours for 3 days). We used Isoflurane as an anesthetic (induction with 4% and maintenance with 1-1.5% in O 2 ; 3l/min). Adequate depth of anesthesia was confirmed. After surgery, animals were placed back to the mother as soon as they were awake, able to right themselves and able to move about. We monitored several parameters including anesthetic depth (persistence), clinical signs and condition. We monitored the pups every hours for at least 6-8 hours post operation with special attention to breathing pattern and mobility, as well as signs of seepage or bleeding from the incision. When neonates have reached the age of interest, animals were 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 Slides were rinsed in ddH2O, counterstained in Cresyl violet (Nissl body staining for neuronal structure and gross brain morphology), dehydrated in a series of ethanol baths (95% >100%) and xylene, and mounted with Eukitt (Sigma-Aldrich, St. Louis, MO). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 The western blots using antibodies specific motifs were performed as we had described previously [1] . To dissect WJ-MSCs protective mechanisms in the brain tissue (n=3 each group), we induced brain injury as previously described [1, 2] . Injury and Injury+WJ-MSCs groups received Lipopolysaccharides (LPS 0.1mg/kg BW, i.p.)
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at postnatal day 2 (P2). On the following day, left common carotid artery was doubleligated using a stereomicroscope and animals were subjected to hypoxia (8% O 2 / 92% N 2 ; 65 minutes). The Sham Group consisted of uninjured animals (0.9% NaCl instead of LPS i.p., exposure of carotid artery without ligation, no hypoxia and received no treatment. The Injury Group received no further treatment but ne needle was placed into the ventricle. The Injury+WJ-MSCs Group received a single cell graft transplantation into the lateral ventricle. We transplanted 250'000 of WJ-MSCs into the ventricle at postnatal day 4 as published previously [3] . We harvested the brain tissue at P11 and evaluated specific motif. antibodies as previously performed [2] . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
